Literature DB >> 29427266

Correction to: ACMT Position Statement: Addressing the Rising Cost of Prescription Antidotes.

Maryann Mazer-Amirshahi1, Andrew Stolbach2, Lewis S Nelson3.   

Abstract

This article contains a couple typographical errors in the table and in the formatting of references. The authors and the journal apologize for those errors and respectfully include a corrected table and corrected reference list here.

Year:  2018        PMID： 29427266      PMCID： PMC5962464          DOI： 10.1007/s13181-018-0652-x

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN： 1556-9039


  8 in total

1.  Using market-exclusivity incentives to promote pharmaceutical innovation.

Authors:  Aaron S Kesselheim
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

2.  High-cost generic drugs--implications for patients and policymakers.

Authors:  Kathleen Uhl; John R Peters; Keith Flanagan
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

3.  Rising cost of antidotes in the U.S.: cost comparison from 2010 to 2015.

Authors:  Gregory A Heindel; Jeanette D Trella; Kevin C Osterhoudt
Journal:  Clin Toxicol (Phila)       Date:  2017-02-06       Impact factor: 4.467

4.  Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs.

Authors:  Panos Kanavos; Alessandra Ferrario; Sotiris Vandoros; Gerard F Anderson
Journal:  Health Aff (Millwood)       Date:  2013-04       Impact factor: 6.301

Review 5.  The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.

Authors:  Aaron S Kesselheim; Jerry Avorn; Ameet Sarpatwari
Journal:  JAMA       Date:  2016 Aug 23-30       Impact factor: 56.272

6.  Orphan Drug Expenditures In The United States: A Historical And Prospective Analysis, 2007-18.

Authors:  Victoria Divino; Mitch DeKoven; Michael Kleinrock; Rolin L Wade; Satyin Kaura
Journal:  Health Aff (Millwood)       Date:  2016-09-01       Impact factor: 6.301

Review 7.  Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States.

Authors:  R C Dart; L R Goldfrank; P A Chyka; D Lotzer; A D Woolf; J McNally; W R Snodgrass; K R Olson; E Scharman; R J Geller; D Spyker; M Kraft; R Lipsy
Journal:  Ann Emerg Med       Date:  2000-08       Impact factor: 5.721

Review 8.  Why are cancer drugs so expensive in the United States, and what are the solutions?

Authors:  Hagop Kantarjian; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2015-03-16       Impact factor: 7.616
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.